The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies | Zendy

Rice K. L. | Zendy; Thé H. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies

Author(s) -

Rice K. L.,

Thé H.

Publication year - 2014

Publication title -

journal of internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.625

H-Index - 160

eISSN - 1365-2796

pISSN - 0954-6820

DOI - 10.1111/joim.12208

Subject(s) - arsenic trioxide , medicine , epigenetics , acute promyelocytic leukemia , pathogenesis , disease , tretinoin , retinoic acid , oncology , cancer research , bioinformatics , immunology , gene , genetics , apoptosis , biology

The recent finding that almost all patients with acute promyelocytic leukaemia ( APL ) may be cured using a combination of retinoic acid ( RA ) and arsenic trioxide ( A s 2 O 3 ) ( N Engl J Med , 369, 2013 and 111) highlights the progress made in our understanding of APL pathogenesis and therapeutic approaches over the past 25 years. The study of APL has revealed many important lessons related to transcriptional control, nuclear organization, epigenetics and the role of proteolysis in biological control. Even more important has been the clinical demonstration that molecularly targeted therapy can eradicate disease.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research